

Amendments to the Specification:

Please amend paragraph 0025 of the specification as follows:

[0025] Other useful pressure-sensitive adhesives ("PSA") can include acrylic-based pressure-sensitive adhesives and silicone-based pressure-sensitive adhesives as described in U.S. Pat. Nos. 5,474,783, and ~~5,656,386~~ 5,656,286. Suitable commercially available acrylic-based polymers can include adhesives that are commercially available and include the polyacrylate adhesives sold under the trademarks Duro-Tak by National Starch and Chemical Corporation, Bridgewater, N.J., such as Duro-Tak 87-2194, Duro-Tak 87-2196, Duro-Tak 87-1197, 87-4194, 87-2510, 87-2097 and 87-2852. Other suitable acrylic-based adhesives are those sold under the trademarks Gelva-Multipolymer Solution (GMS) (Monsanto; St. Louis, Mo.), such as GMS 737, 788, 1151, 3087 and 7882.

Please amend paragraph 0034 of the specification as follows:

[0034] Illustrative examples of suitable adhesives and flexible, finite delivery systems include those described in U.S. Patent Nos. 5,474,783, and ~~5,656,386~~ 5,656,286 both assigned to Noven Pharmaceuticals, Inc., Miami, Florida (incorporated herein by reference).

Please amend paragraph 0048 of the specification as follows:

[0048] In some instances, the steady decrease may be broadly considered, "substantially zero-order" as that term is used in co-owned Serial No. ~~09/161,351~~ 09/163,351, from which this application claims priority, in that the variability contemplated within the scope of "substantially zero order" of about a 30% to about 40% difference from the mean in the plasma levels of methylphenidate at steady state (6-16 hours after administration) would also include a 30 to 40% decrease from the mean plasma levels of methylphenidate.